0001562180-19-005195.txt : 20191018
0001562180-19-005195.hdr.sgml : 20191018
20191018171344
ACCESSION NUMBER: 0001562180-19-005195
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191016
FILED AS OF DATE: 20191018
DATE AS OF CHANGE: 20191018
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Truitt Joseph
CENTRAL INDEX KEY: 0001452429
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33095
FILM NUMBER: 191158395
MAIL ADDRESS:
STREET 1: C/O ACHILLION PHARMACEUTICALS, INC.
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACHILLION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070336
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-624-7000
MAIL ADDRESS:
STREET 1: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2019-10-16
false
0001070336
ACHILLION PHARMACEUTICALS INC
ACHN
0001452429
Truitt Joseph
C/O ACHILLION PHARMACEUTICALS, INC.
1777 SENTRY PARKWAY W, BLDG 14, STE 200
BLUE BELL
PA
19422
true
true
false
false
Chief Executive Officer
Common Stock
2019-10-16
4
M
false
100234.00
3.10
A
103734.00
D
Common Stock
2019-10-16
4
M
false
33250.00
3.28
A
136984.00
D
Common Stock
2019-10-16
4
S
false
100234.00
6.3749
D
36750.00
D
Common Stock
2019-10-16
4
S
false
33250.00
6.3749
D
3500.00
D
Stock Option (Right to Buy)
3.28
2019-10-16
4
M
false
33250.00
0.00
D
2019-12-18
Common Stock
33250.00
0.00
D
Stock Option (Right to Buy)
3.10
2019-10-16
4
M
false
100234.00
0.00
D
2020-12-16
Common Stock
100234.00
87766.00
D
This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
This option was granted on December 16, 2010 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Truitt on March 8, 2018.
/s/ Joseph Truitt
2019-10-18